UNSPSC 51142533: Memantine

This classification denotes a neuroprotective agent and antiparkinsonian agent with the molecular formula C12H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8O17SJF3T, chemically known as 3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine but generally known as memantine, which bears US NIH Compound Identifier 4054. European Medicines Agency schedules Memantine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08731MIG.

UNSPSC 51142533 Memantine is a Commodity code that nominally describes a specific pharmaceutical active ingredient, yet recent state and local solicitations tagged under this code are actually procuring a broad range of pharmaceutical and medical products—naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products—through direct purchase and cooperative purchasing frameworks. State and local governments are using this code to acquire both branded and generic drugs, medical countermeasures, and OTC supplies to support public health, community health initiatives, and employee health benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). The mix reflects a shift toward consolidated pharmaceutical procurement through both direct vendor relationships and authorized-wholesaler networks rather than individual product-line acquisitions.

Recent activity spans Florida, Texas, and Minnesota through multi-state vehicles. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date and quarterly deliveries to its Community Health Building in Sanford. Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers and group purchasing organizations, reflecting preliminary market intelligence gathering before formal RFP issuance. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, seeking multiple awards for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. All three solicitations require vendor compliance with federal manufacturing and supply-chain standards, insurance certifications, and electronic ordering systems; none identify explicit set-asides for disadvantaged enterprises in available documentation.